Dominic Piscitelli Sells 2,600 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 2,600 shares of the business's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.01, for a total value of $26,026.00. Following the completion of the transaction, the chief financial officer now directly owns 104,164 shares of the company's stock, valued at approximately $1,042,681.64. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Dominic Piscitelli also recently made the following trade(s):

• On Wednesday, June 11th, Dominic Piscitelli sold 2,976 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total value of $29,789.76.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total value of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total value of $3,000.00.

ORIC Pharmaceuticals Stock Performance

ORIC traded up $0.28 on Thursday, hitting $9.67. 814,754 shares of the company were exchanged, compared to its average volume of 773,618. ORIC Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.67. The company has a market cap of $687.42 million, a PE ratio of -5.31 and a beta of 1.49. The stock's fifty day moving average is $6.04 and its 200-day moving average is $7.71.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.09. As a group, equities research analysts expect that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Cantor Fitzgerald restated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday, May 6th. Oppenheimer cut their price target on ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Finally, Wedbush reiterated an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a report on Thursday, May 29th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $19.17.

Institutional Trading of ORIC Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. raised its stake in ORIC Pharmaceuticals by 8.5% in the fourth quarter. Invesco Ltd. now owns 23,958 shares of the company's stock valued at $193,000 after buying an additional 1,876 shares during the period. PNC Financial Services Group Inc. raised its stake in ORIC Pharmaceuticals by 22.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after buying an additional 2,520 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in ORIC Pharmaceuticals by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock valued at $226,000 after buying an additional 3,131 shares during the period. Swiss National Bank raised its stake in ORIC Pharmaceuticals by 5.4% in the fourth quarter. Swiss National Bank now owns 62,400 shares of the company's stock valued at $504,000 after buying an additional 3,200 shares during the period. Finally, Rhumbline Advisers raised its stake in ORIC Pharmaceuticals by 4.6% in the fourth quarter. Rhumbline Advisers now owns 93,319 shares of the company's stock valued at $753,000 after buying an additional 4,072 shares during the period. Institutional investors own 95.05% of the company's stock.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.